GGiantBullStocks

Kura Oncology, Inc. (KURA)

NASDAQ · Healthcare

$10.68-1.66%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$961.43M
P/E ratio
EPS
Volume
799,313
52-week high
52-week low
Open
$11.01
Day high
$11.16
Day low
$10.67

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$67.48M-$278.67M-$3.18
2024$53.88M-$173.98M-$2.02
2023$0-$152.63M-$2.08
2022-$135.84M-$2.03
2021-$130.47M-$1.97

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

CEO
Troy Wilson
Employees
260
Country
US
IPO date
Sep 16, 2015

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Kura Oncology, Inc.'s stock price today?
KURA is trading at $10.68 as of Jul 20, 2026.
What is Kura Oncology, Inc.'s market cap?
Kura Oncology, Inc. (KURA) has a market capitalization of $961.43M.
Does Kura Oncology, Inc. pay a dividend?
Kura Oncology, Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Kura Oncology, Inc. in?
Kura Oncology, Inc. operates in the Healthcare sector.